Trial · NCT04485195
RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
NCT04485195, Phase 4, Completed, Ottawa Hospital Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department. Trials, record NCT04485195. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04485195
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
- NCT number
- NCT04485195
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 350 participants, actual
- Lead sponsor
- Ottawa Hospital Research Institute
- Conditions
- Atrial Fibrillation
- Interventions
- Vernakalant, Procainamide
- First posted
- 2020-07-24
- Last updated
- 2025-04-10
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Conversion to sinus rhythm for a minimum duration of 30 minutes | During any time following randomization until 30 minutes past the completion of the drug infusion | Conversion to and maintenance of sinus rhythm for at least 30 minutes at any time following randomization until 30 minutes past the completion of the drug infusion. Heart rhythm will be determined by an electrocardiogram (ECG). |
| Secondary | Normal sinus rhythm | At the time of patient disposition (approximately 3 hours after arrival) | Being in normal sinus rhythm at the time of ED disposition (discharge or admission). Heart rhythm will be determined by an electrocardiogram (ECG). |
| Secondary | Patient disposition (admission or discharge) | At the time of patient admission or discharge (approximately 3 hours after arrival) | Whether the patient was discharged home or admitted to the hospital. |
| Secondary | Length of stay in ED | From time of arrival until time of discharge or admission (approximately 3 hours) | Length of stay in ED in minutes, from time of arrival to time of discharge or admission |
| Secondary | Time to discharge | From time of randomization until time of discharge or admission (approximately 3 hours) | Time to discharge in minutes, from time of randomization to time of discharge or admission |
| Secondary | Time to conversion | From time of infusion start until time of conversion to sinus rhythm (approximately 0 - 90 minutes) | Time to conversion to sinus rhythm in minutes, from time of start of study drug infusion |
| Secondary | Whether the patient required electrical cardioversion | From 30 minutes after the study drug infusion is completed. | Whether the patient required electrical cardioversion to restore normal sinus rhythm in the ED |
| Secondary | Adverse events | 0-12 hours | will be classified as serious or other, whether occurring 0-2 hours or 2-12 hours after infusion, whether infusion had to be halted or discontinued, or treatment required |
| Other | Maintenance of normal sinus rhythm | 30 days post discharge | Maintenance of normal sinus rhythm at 30 days after ED disposition, to be verified by hospital records, patient report, or by a smartphone application. |
| Other | Recurrence of acute AF | 30 days | Recurrence of acute atrial fibrillation requiring an emergency department visit |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41218981 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04485195
GET https://conductscience.org/api/trials/v1/NCT04485195/registered